Unicycive Therapeutics UNCY Insider Ownership

NASDAQ UNCY
$3.78 +0.12 (+3.28%)
At close: Nov 11, 2026 · 4:00 PM EST

Insider Holdings by Owner

2.07Mn Shares
Gaurav Aggarwal1.79Mn86.6%
Shalabh K. Gupta252.74K12.2%
Douglas Jermasek17.50K0.8%
Pramod Gupta4.18K0.2%
Brigitte Schiller2.67K0.1%

Insider Ownership Statistics

as of 30 Sep, 2026
Insider Ownership
7.41%
■0% pp QoQ
Shares Held by Insiders
2.06Mn
filed for Sep 2026
■0.00% QoQ
Shares Outstanding
27.86Mn
27,855,257 shares
Direct Holdings
274.43K
Indirect: 1.79Mn
Net Open-Market Trades
0
no open-market trades in Sep 2026
Insiders Holding Shares
5
with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding
Latest —
Average ownership —
Peak ownership —

Open-Market Insider Trades

Bought Sold
Latest quarter —
Net over range —
Net-buying quarters —

Insider Ownership Summary

Updated

Across the past 12 months, Unicycive Therapeutics insiders reported no open-market purchases or sales.

Form 4 Holdings

Insiders Holding UNCY

Insiders 5
Shares held 2.07Mn
Of outstanding 7.42%
# Insider Position Direct Indirect Total Share of Insiders Last Filed
1 Gaurav Aggarwal Director 0 1,789,915 1,789,915 86.6% 26 Aug, 2025
2 Shalabh K. Gupta Ceo 252,745 0 252,745 12.2% 13 Jul, 2023
3 Douglas Jermasek Evp Of Corporate Strategy 17,501 0 17,501 0.8% 13 Jul, 2023
4 Pramod Gupta Evp, Pharmaceuticals And Bd 4,185 0 4,185 0.2% 13 Jul, 2023
5 Brigitte Schiller Director 2,674 0 2,674 0.1% 30 Aug, 2022

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

84 Insider Transactions

Source SEC Form 4
Latest quarter Sep 2026
Download Data
Date Insider Position Transaction Shares Price Value Shares Held After Ownership
28 Oct, 2026 Meredith Manning Director Acquired A 3,350 $0.00 $0 3,350 Direct
28 Oct, 2026 Meredith Manning Director Acquired A 27,000 $0.00 $0 27,000 Direct
14 May, 2026 Sandeep Laumas Director Acquired A 47,941 $0.00 $0 47,941 Direct
14 May, 2026 Sara Kenkare-Mitra Director Acquired A 47,941 $0.00 $0 47,941 Direct
14 May, 2026 Sandeep Laumas Director Acquired A 84,200 $0.00 $0 84,200 Direct
14 May, 2026 Shalabh K. Gupta Ceo Acquired A 762,200 $0.00 $0 762,200 Direct
14 May, 2026 Douglas Jermasek Evp, Corporate Strategy Acquired A 169,500 $0.00 $0 169,500 Direct
14 May, 2026 Sara Kenkare-Mitra Director Acquired A 84,200 $0.00 $0 84,200 Direct
14 May, 2026 John Townsend Cfo Acquired A 169,500 $0.00 $0 169,500 Direct
14 May, 2026 Pramod Gupta Evp, Pharmaceuticals And Bd Acquired A 169,500 $0.00 $0 169,500 Direct
14 May, 2026 Sara Kenkare-Mitra Director Acquired A 42,100 $0.00 $0 126,300 Direct
14 May, 2026 Sandeep Laumas Director Acquired A 42,100 $0.00 $0 126,300 Direct
14 May, 2026 Shalabh K. Gupta Ceo Acquired A 762,200 $0.00 $0 762,200 Direct
14 May, 2026 Sara Kenkare-Mitra Director Acquired A 84,200 $0.00 $0 84,200 Direct
14 May, 2026 Sara Kenkare-Mitra Director Acquired A 42,100 $0.00 $0 126,300 Direct
14 May, 2026 Pramod Gupta Evp, Pharmaceuticals And Bd Acquired A 169,500 $0.00 $0 169,500 Direct
14 May, 2026 Douglas Jermasek Evp, Corporate Strategy Acquired A 169,500 $0.00 $0 169,500 Direct
14 May, 2026 John Townsend Cfo Acquired A 169,500 $0.00 $0 169,500 Direct
14 May, 2026 Sandeep Laumas Director Acquired A 84,200 $0.00 $0 84,200 Direct
14 May, 2026 Sandeep Laumas Director Acquired A 42,100 $0.00 $0 126,300 Direct